Haofeng Medical Secures CNY 100M Series A for Interventional Device CDMO Expansion | VeilStrat

Haofeng Medical (昊丰医疗), a Shanghai-based contract development and manufacturing organization (CDMO) specializing in Class III interventional medical devices, has raised CNY 100 million in a Series A funding round. The investment was led by Huayin Jintou (华银金投), according to a recent filing. The funding will support the company's expansion, including the construction of a new AI-enabled digital factory in Taizhou's China Medical City.

What Haofeng Medical Does

Founded in 2013, Haofeng Medical provides comprehensive CDMO services for interventional medical devices, covering research and development support, pre-registration manufacturing, and post-market contract production. The company operates four technology platforms:

Access components (balloons, catheters, guidewires)
Medical-grade materials
Production and testing equipment
Energy-based active devices

These platforms enable Haofeng to serve clients across various interventional fields, including neurovascular, coronary, peripheral, structural-heart, and electrophysiology.

Company Achievements

Haofeng Medical reports serving more than 60 clients domestically and internationally, with over 30 overseas clients. The company is building a new AI-enabled digital factory in Taizhou's China Medical City, which is expected to enhance its manufacturing capabilities and efficiency.

Funding Details

Round Type: Series A
Amount: CNY 100 million
Lead Investor: Huayin Jintou (华银金投)
Funding Date: September 1, 2026

This Series A funding will enable Haofeng Medical to accelerate its growth, expand its manufacturing capacity, and further develop its technology platforms. The investment underscores the growing demand for specialized CDMO services in the interventional medical device sector, particularly in China's rapidly evolving healthcare market.

As Haofeng Medical continues to expand, it aims to strengthen its position as a leading partner for medical device companies seeking high-quality, cost-effective manufacturing solutions. The new funding will play a crucial role in supporting the company's strategic initiatives and long-term growth plans.